TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Part 1:~* Males or females aged 50-74 years, inclusive, at the time of informed consent~* Diagnosed with mild Alzheimers disease, including CSF biomarkers consistent with this diagnosis~* Body Mass Index BMI ≥ 18 and ≤ 35 kg/m2 and total body weight \> 50 kg (110 lbs)~* Able and willing to meet all study requirements, including toleration for MRI scans, blood draws and lumbar punctures, travel to Study Center and participation in all procedures and measurements at study visits~* Have a trial partner who is reliable, competent and at least 18 years of age, is willing to accompany the patient to select trial visits and to be available to the Study Center by phone if needed~* Reside within 4 hours travel of the Study Center~Exclusion Criteria for Part 1:~* Treatment with another Study Drug, biological agent, or device within one-month of Screening or 5 half-lives of investigational agent, whichever is longer~* Clinically significant medical condition which would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study~* Use of a disallowed CNS-active or antipsychotic medication within 4 weeks prior to Screening punctures~Inclusion Criteria for Part 2:~* Must have completed the Treatment Evaluation and Post-Treatment Periods in Part 1~Exclusion Criteria for Part 2 (only applicable to participants in Cohorts A and B, as participants from Cohorts C and D will seamlessly transition to Part 2):~* Treatment with another Study Drug, biological agent, or device within one-month of Screening or 5 half-lives of investigational agent, whichever is longer~* Clinically significant medical condition which would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study~* Use of a disallowed CNS-active or antipsychotic medication within 4 weeks prior to Screening punctures

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- IONIS-MAPTRx (Type: EXPERIMENTAL): IONIS MAPTRx (Study Drug)
- Placebo (Type: PLACEBO_COMPARATOR): Artificial CSF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for cohort 1:~* Aged 18 years or over~* Moderate-to-severe UC, defined as:~SCCAI \> 5 and, i. A raised fecal calprotectin (\> 59 μg/g) or, ii. A raised CRP (\> 5 mg/L) or, iii. Endoscopic disease activity Mayo 2 or above, Evaluated within 4 weeks of study enrollment~* Commencing golimumab treatment~* Written informed consent to participate~* Sufficient English language skills to understand the patient information sheet and consent form~Inclusion Criteria for cohort 2:~* Aged 18 years or over~* Receiving golimumab treatment for UC for over 18 weeks (6 injections)~* Written informed consent to participate~* Sufficient English language skills to understand the patient information sheet and consent form~Exclusion Criteria (cohort 1 only):~* Contra-indication to golimumab: tuberculosis or severe infections~* Imminent need for colectomy (i.e. colectomy is being planned)~* Previous primary non-response to anti-TNF therapy in the opinion of the investigator~* Previous treatment with more than one anti-TNF therapy (excluding golimumab)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction cohort (Type: OTHER): Golimumab induction therapy
- Maintenance cohort (Type: OTHER): Golimumab maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject presents with duration of chronic low back pain of \> 3 months requiring regular use of analgesics (\> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used~Exclusion Criteria:~* The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- celecoxib (Type: EXPERIMENTAL): None
- tramadol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fever (either self-reported or objectively measured, e.g. axillary temperature ≥38oC, with a date of onset between 1-4 days prior to the day of presentation.~* Aged ≥3 years old.~* Lived (i.e. slept) in the study area every night (or day) for the 10 days preceding illness onset.~Exclusion Criteria:~* Localising features suggestive of a specific diagnosis e.g. severe diarrhea, otitis, pneumonia~* Prior enrollment in the study within the previous 4 weeks.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early-release (Type: None): Resident in areas that receive early Wolbachia deployments.
- Late-release (Type: None): Resident in areas that receive late Wolbachia deployments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical history of asthma~* Forced expiratory volume in 1 second between 60% and 90% of predicted~* Using an inhaled corticosteroid (ICS)at a dose equivalent to 200 to 500 mcg daily of beclomethasone (BDP)or equivalent combined with a long-acting beta-2-agonist or an ICS alone at a dose equivalent to \>500 to 1000mcg daily of BDP daily~Exclusion Criteria:~* Lower respiratory tract infection within 1 month of study entry~* Use of systemic corticosteroids within 1 month of study entry~* Smoking history of 10 pack years or more Changes in regular asthma therapy within 12 weeks of study entry~* Any significant disorder that in the investigator's opinion might put the patient at risk or influence the study outcomes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is \>18 years and male or female of any race / ethnicity~* Patient or patient's legally acceptable representative provides written informed consent and is willing to comply with protocol procedures~* Patient must have histopathologically confirmed head/neck, lung, liver, rectal or cervical cancer with tumor size ≥ 3cm~* Patient has tumor tissue samples available before treatment for future immunohistochemistry biomarker tests (HIF1alpha and CA-IX)~* Patient is scheduled to have or already had a clinical \[F 18\]FDG PET/CT scan recommended to be within 14 days of the first pre-treatment \[F 18\]HX4 PET/CT scan and have no treatment intervention in between these two scans~* Patient is scheduled or is intended to be scheduled to receive chemotherapy, radiation or chemoradiotherapy treatment(s) after the pre-treatment \[F 18\]HX4 PET/CT and \[F 18\]FDG PET/CT scans for his/her cancer care~* Patient must have hepatic and renal functions as defined by laboratory results within the following ranges:~  * Total bilirubin within 2 times institutional upper limit of normal~ * AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional upper limits of normal~ * Serum creatinine ≤ 2.5 times institutional limit of normal~ * BUN within 2 times institutional upper limit of normal~Exclusion Criteria:~* Patient is not capable of complying with study procedures~* Female patient is pregnant or nursing~  o Exclude the possibility of pregnancy by one of the following:~ * Confirming in medical history that the patient is post-menopausal for a minimum of one year, or surgically sterile~ * Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: IUD, oral contraceptives, Depo-Provera, or Norplant~ * Confirming a negative urine dipstick test taken the morning of but before receiving \[F 18\]HX4~* Patient has been involved in an investigative, radioactive research procedure within 7 days and during the study participation period~* Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [F 18]HX4 (Type: EXPERIMENTAL): \[F18\]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and Men between 18 and 80 years of age inclusive~* Have refractory chronic cough~* Women of child-bearing potential must use 2 forms of acceptable birth control - Have provided written informed consent.~* Are willing and able to comply with all aspects of the protocol~Exclusion Criteria:~* Current smoker~* Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio \<60%~* History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit~* History of opioid use within 1 week of the Baseline Visit~* Body mass index (BMI) \<18 kg/m\^2 or ≥ 40 kg/m\^2~* History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with \<3 excised basal cell carcinomas)~* Screening systolic blood pressure (SBP) \>160 mm Hg or a diastolic blood pressure (DBP) \>90 mm Hg~* Clinically significant abnormal electrocardiogram (ECG) at Screening~* Significantly abnormal laboratory tests at Screening~* Pregnant or Breastfeeding~* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the participant inappropriate for entry into this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 7.5 mg (Type: EXPERIMENTAL): Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 20 mg (Type: EXPERIMENTAL): Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 50 mg (Type: EXPERIMENTAL): Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 15-90 years~* Either gender~* Patients diagnosed with COVID-19 disease by RT-PCR~* Have confirmed COVID-19 symptoms and symptom onset within the past 10 days~* Capable of using a nasal spray device and perform nasal irrigation required by the study~* Willing to participate~Exclusion Criteria:~* Patient with known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients~* Previously diagnosed thyroid disease~* Patients with chronic renal failure (stage ≥3 by estimated Glomerular Filtration rate (eGFR) Modification of Diet in Renal Disease( MDRD)~* Patients with acute renal failure (KDIGO ≥stage 2: creatinine ≥2 X baseline)~* Pregnant and lactating mother~* Current requirement for invasive or non-invasive ventilation or planned within next 6 hours.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- PVP-I 0.4% NI (Type: EXPERIMENTAL): Arm-1 will receive Povidone iodine (PVP-I) nasal irrigation (NI) at concentration of 0.4% single time
- PVP-I 0.5% NI (Type: EXPERIMENTAL): Arm-2 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5% single time
- PVP-I 0.6% NI (Type: EXPERIMENTAL): Arm-3 will receive Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6% single time
- PVP-I NS 0.5% NS (Type: EXPERIMENTAL): Arm-4 will receive will receive PVP-I nasal spray (NS) at concentration of 0.5% single time
- PVP-I 0.6% NS (Type: EXPERIMENTAL): Arm-5 will receive will receive PVP-I nasal spray at concentration of 0.6% single time
- DW NI (Type: PLACEBO_COMPARATOR): Arm-6 will receive distilled water through nasal irrigation
- DW NS (Type: PLACEBO_COMPARATOR): Arm-7 will receive distilled water through nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-70 years of age.~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder.~* The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration.~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for any:~  * manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;~ * any depressive episode with psychotic or catatonic features;~ * panic disorder with or without agoraphobia;~ * obsessive-compulsive disorder;~ * schizophrenia, schizoaffective, or other psychotic disorder;~ * bulimia or anorexia nervosa;~ * presence of borderline personality disorder or antisocial personality disorder;~ * mental retardation, dementia, amnesia, or other cognitive disorders;~ * patients who are considered a suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dose-matched placebo (Type: PLACEBO_COMPARATOR): Participants received dose-matched placebo orally once daily for 9 weeks.
- Vilazodone (Type: EXPERIMENTAL): Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with chronic, plaque-type psoriasis for at least 6 months~* Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area~* Must be inadequately controlled by prior treatments (topicals, phototherapy, and/or systemic therapies)~Exclusion Criteria:~* Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermic and guttate psoriasis)~* Drug induced psoriasis~* Use of other psoriasis treatments during the study~* Prior use of etanercept~* Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or the IL-17 receptor~* Pregnant or lactating women; women who do not agree to use contraception during the study and for 16 weeks after stopping treatment~* Significant medical problems such as uncontrolled high blood pressure, congestive heart failure, etc.~* History of an ongoing, chronic or recurrent infection or evidence of tuberculosis~* Allergy to rubber or latex~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150mg (Type: EXPERIMENTAL): AIN457 150mg
- AIN457 300mg (Type: EXPERIMENTAL): AIN457 300mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Etanercept (Type: ACTIVE_COMPARATOR): Etanercept
- AIN457 150mg from Placebo (Type: EXPERIMENTAL): Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
- AIN457 300mg from Placebo (Type: EXPERIMENTAL): Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray Compared to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 12 years;~* Acute pharyngitis or tonsillitis with symptoms of throat pain and inflammation of the pharynx and/or tonsils;~* Onset of sore throat less than 72 hours before inclusion ;~* A Tonsillopharyngitis Severity Score ≥6;~* Written informed consent.~Exclusion Criteria:~* Analgesics \<12 hours;~* Antibiotics \<24 hours; t~* Topical throat pain medication \<4 hours;~* Systemic corticosteroids within the last month;~* Symptoms of primary bacterial pharyngitis or secondary bacterial infection;~* Serious illness such as tumors; allergy to one of the ingredients; pregnancy or lactation;~* Hypersensitivity to ibuprofen;~* Participation in another clinical trial in the previous 30 days.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1
- 1 (Type: ACTIVE_COMPARATOR): Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HPV Message Testing and Social Media Campaign

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* parents of children 9-14 years old~Exclusion Criteria:~* non-parents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HPV Messaging (Type: EXPERIMENTAL): Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
- Control Message (Type: OTHER): Subjects are randomized to receive one of five messages about electronic cigarettes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete